Atea Pharmaceuticals (AVIR) EBIT Margin (2021)
Atea Pharmaceuticals' EBIT Margin history spans 1 years, with the latest figure at 63.06% for Q4 2021.
- Quarterly EBIT Margin changed N/A to 63.06% in Q4 2021 from the year-ago period, while the trailing twelve-month figure was 39.38% through Dec 2021, changed N/A year-over-year, with the annual reading at 39.38% for FY2021, 6206.0% up from the prior year.
- EBIT Margin came in at 63.06% for Q4 2021, up from 67.5% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 63.06% in Q4 2021 to a low of 67.5% in Q3 2021.